Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel (MATTIS-D)
|First Received Date ICMJE||July 15, 2012|
|Last Updated Date||June 14, 2013|
|Start Date ICMJE||August 2012|
|Estimated Primary Completion Date||September 2014 (final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
||Rate of elevation of troponin or CK-MB (above the upper limit of normal, and above 3 times the upper limit of normal) measured 20-24 hours after the PCI. [ Time Frame: 20-24 hours after the PCI ] [ Designated as safety issue: No ]
Rate of elevation of troponin or CK-MB (above the upper limit of normal, and above 3 times the upper limit of normal) measured 20-24 hours after the PCI.
|Original Primary Outcome Measures ICMJE||Same as current|
|Change History||Complete list of historical versions of study NCT01643031 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE
||Rate of major adverse cardiovascular endpoints including death, myocardial infarction or urgent target vessel revascularization at 30 days [ Time Frame: 30 days ] [ Designated as safety issue: No ]
Rate of major adverse cardiovascular endpoints including death, myocardial infarction or urgent target vessel revascularization at 30 days
|Original Secondary Outcome Measures ICMJE||Same as current|
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel|
|Official Title ICMJE||Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel|
In recent years numerous studies have shown that the response of patients to the anti-platelet drug clopidogrel is widely variable. Furthermore, patients who do not respond well to the drug ("resistant") have been shown to be at increased risk to develop cardiac events, including myocardial infarction and mortality. It thus seems reasonable to test the efficacy of the drug (by platelet function tests) and modify treatment accordingly. However, a large study that examined a strategy of routine testing of clopidogrel response in thousands of patients (GRAVITAS study) did not show any clinical benefit. This study was limited, however, by a very low event rate (2.3%), and by the strategy employed to treat patients with low response (increasing the clopidogrel dose), which is currently known to be ineffective in many patients with low response. To overcome these limitations the investigators plan to examine a high risk population - patients with diabetes planned to undergo coronary angiography - and to treat clopidogrel low responders by switching their treatment to the potent anti-platelet drug ticagrelor, which has been shown to overcome clopidogrel low response.
The investigators hypothesize that patients with diabetes and low response to clopidogrel will benefit clinically from switching therapy to ticagrelor. The main endpoint of the study will be the risk of myocardial enzyme elevation following percutaneous coronary intervention (PCI); a marker which has been strongly associated with poor clinical outcome.
The aim of the study is, therefore, to assess whether a strategy of monitoring platelet function during clopidogrel treatment in patients with diabetes undergoing PCI, and modifying treatment to ticagrelor in patients with low response, will be associated with reduced risk of myocardial enzyme release.
The investigators plan to enroll patients with treated diabetes, planned to undergo coronary angiography. Patients with acute or recent myocardial infarction will be excluded. They will be tested for response to clopidogrel by the VerifyNow P2Y12 assay (either on chronic clopidogrel treatment or 12-24 hours after receiving 300 mg clopidogrel). Patients with low response to clopidogrel (≥ 208 PRU) will be randomized to either continued treatment with clopidogrel (75 mg/day), or switching of treatment to ticagrelor (90 mg twice a day) for 30 days (followed by continued clopidogrel therapy). The primary endpoint will be the rate of troponin of CK-MB (cardiac enzymes) measured 20-24 hours after the PCI. Secondary endpoints will be the occurrence of adverse clinical endpoints - myocardial infarction, need for urgent revascularization or mortality at 30 days. The investigators aim to enroll 100 patients in each study group (ticagrelor vs. continued clopidogrel). Assuming a clopidogrel low response rate of 40% among patients with diabetes, about 500 patients would have to be screened to identify 200 patients with low response.
BACKGOUND The concept of monitoring platelet reactivity in patients treated with clopidogrel and tailoring treatment according to the results has been under intense debate in recent years. There is clear and consistent evidence that there is wide variability in the anti-platelet response to clopidogrel, and that patients with low response (more accurately termed - high on treatment platelet reactivity) are at increased risk of adverse cardiac events - mainly stent thrombosis and myocardial infarction. However, the only large randomized trial that examined a strategy of routing monitoring of platelet reactivity and response to clopidogrel and tailoring treatment accordingly (by increasing the clopidogrel maintenance dose) - the GRAVITAS study - was negative. Thus, although from a physiological perspective it seems reasonable to monitor the effects of a drug with such wide variability (and poor prognosis associated with low response), clinical evidence in support of routine monitoring is lacking. When analyzing the negative results of the GRAVITAS study, two main factors should be discussed: a very low clinical adverse event rate (2.3% in each of study the groups) probably reflecting a low risk patient population, and the strategy chosen to overcome high on treatment platelet reactivity (HTPR) - increasing the maintenance clopidogrel dose from 75 mg daily to 150 mg daily, which is currently known to be ineffective in overcoming clopidogrel HTPR in many of the patients.
In light of these potential limitations of the GRAVITAS study the investigators propose a study based on the following aspects:
The aim of the study is to assess whether a strategy of monitoring platelet reactivity during clopidogrel treatment in patients with diabetes undergoing PCI, and modifying the treatment to ticagrelor in patients with HTPR, is associated with a lower rate of myocardial enzyme elevation following PCI.
See inclusion and exclusion criteria in the following sections.
Patients treated chronically with clopidogrel 75 mg per day will undergo platelet function testing under this treatment regimen. Patients who are clopidogrel naïve will be given 300 mg loading of clopidogrel and be tested about 12-24 hours after this loading dose. For all patients, platelet function testing will be performed before the coronary angiography.
Platelet function testing will be performed with the VerifyNow P2Y12 assay (Accumetrics Inc.), using a cutoff value of ≥ 208 reaction units to define HTPR.
Patients with HTPR will be randomized 1:1 to receive either ticagrelor or additional clopidogrel.
Ticagrelor regimen: 180 mg given 1-2 hours before the coronary angiography, followed by 90 mg twice a day for 30 days in case PCI was performed. After 30 days the patient will be invited to a special research clinic in the hospital and his treatment will be switched to clopidogrel (with 300 mg loading, and 75 mg a day thereafter for 11 additional months - for a total period of 1 year). The 30 day ticagrelor period was chosen because prior studies have shown that platelet hyper-reactivity and low response to clopidogrel are prominent in the first days after PCI, and subside significantly within 30 days after the procedure. In addition, most cases of stent thrombosis occur in the first month following PCI.
Clopidogrel regimen: 300 mg given 1-2 hours before coronary angiography (in addition to the previous 300 mg load or chronic clopidogrel therapy the patient received), followed by 75 mg a day for 1 year case PCI was performed.
The investigators aim to enroll a total of 200 patients with HTPR who will undergo PCI - 100 patients in each group (ticagrelor vs. continued clopidogrel). Patients who will not undergo PCI will be withdrawn from the study.
Choice of stent during PCI will be left to the operator's discretion, but given the diabetes status of all patients, use of drug eluting stents will be encouraged. PCI will be performed according to standard practice and operator preferences (regarding to access, pre- and post dilatation etc.). Use of glycoprotein IIb/IIIa inhibitors will be discouraged, unless in bailout situations. Patients who will receive glycoprotein IIb/IIIa inhibitors will be excluded from the analysis.
An additional VerifyNow P2Y12 test will be performed in the 200 patients with initial HTPR, 20-24 hours following the PCI; at this time point troponin and CK-MB levels will also be evaluated.
Primary endpoint: rate of elevation of troponin or CK-MB (above the upper limit of normal, and above 3 times the upper limit of normal) measured 20-24 hours after the PCI.
Secondary endpoint: rate of major adverse cardiovascular endpoints including death, myocardial infarction or urgent target vessel revascularization at 30 days.
Sample size calculation: assuming a rate of CK-MB or troponin elevation post-PCI of 35% among patients with low response to clopidogrel, 100 patients in each group would allow detection of a 50% difference in the primary endpoint between the groups (50% reduction in myocardial enzyme elevation rate with ticagrelor), with an alpha of 0.05 and power of 0.80. Assuming a HTPR rate of 40% using the 208 VerifyNow cutoff value, 500 patients would have to be screened in order to identify 200 patients with HTPR (not taking into consideration the patients that would not require PCI and be withdrawn from the study).
|Study Type ICMJE||Interventional|
|Study Phase||Phase 4|
|Study Design ICMJE||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Study Arm (s)||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Not yet recruiting|
|Estimated Enrollment ICMJE||500|
|Estimated Completion Date||October 2014|
|Estimated Primary Completion Date||September 2014 (final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
|Ages||30 Years to 80 Years|
|Accepts Healthy Volunteers||No|
|Location Countries ICMJE||Israel|
|NCT Number ICMJE||NCT01643031|
|Other Study ID Numbers ICMJE||6793|
|Has Data Monitoring Committee||Yes|
|Responsible Party||eli lev, Rabin Medical Center|
|Study Sponsor ICMJE||Rabin Medical Center|
|Information Provided By||Rabin Medical Center|
|Verification Date||June 2013|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP